{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=9",
    "query": {
      "intervention": "combined treatment",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 13957,
    "total_pages": 1396,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T11:48:23.606Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06332755",
      "title": "Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer(NSCLC)",
        "Head and Neck Squamous Cell Carcinoma(HNSCC)",
        "Renal Cell Carcinoma(RCC)",
        "Urothelial Carcinoma",
        "Malignant Melanoma"
      ],
      "interventions": [
        {
          "name": "Phase 1a: LB-LR1109",
          "type": "DRUG"
        },
        {
          "name": "Phase 1b: LB-LR1109 and Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LG Chem",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 76,
      "start_date": "2024-06-05",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2025-11-24",
      "last_synced_at": "2026-10-14T11:48:23.606Z",
      "location_count": 1,
      "location_summary": "Fairfax, Virginia",
      "locations": [
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06332755"
    },
    {
      "nct_id": "NCT03275285",
      "title": "Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Plasma Cell Myeloma"
      ],
      "interventions": [
        {
          "name": "isatuximab SAR650984",
          "type": "DRUG"
        },
        {
          "name": "carfilzomib",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 302,
      "start_date": "2017-10-25",
      "completion_date": "2025-01-03",
      "has_results": true,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-10-14T11:48:23.606Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Spartanburg, South Carolina",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03275285"
    },
    {
      "nct_id": "NCT01825447",
      "title": "A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone + Naltrexone",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 89,
      "start_date": "2013-07",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2013-10-08",
      "last_synced_at": "2026-10-14T11:48:23.606Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01825447"
    },
    {
      "nct_id": "NCT06191549",
      "title": "Brain Stimulation Enhance Post-stroke Walking Survivors and Healthy Adults",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cerebral Vascular Accident"
      ],
      "interventions": [
        {
          "name": "anodal transcranial direct current stimulation (a-tDCS)",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "21 Years to 90 Years"
      },
      "enrollment_count": 70,
      "start_date": "2025-05-01",
      "completion_date": "2026-08-31",
      "has_results": false,
      "last_update_posted_date": "2025-10-31",
      "last_synced_at": "2026-10-14T11:48:23.606Z",
      "location_count": 1,
      "location_summary": "Galveston, Texas",
      "locations": [
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06191549"
    },
    {
      "nct_id": "NCT03315078",
      "title": "Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "X-Linked Combined Immunodeficiency Diseases"
      ],
      "interventions": [
        {
          "name": "CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Palifermin",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "2 Years to 40 Years"
      },
      "enrollment_count": 13,
      "start_date": "2012-04",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2019-12-04",
      "last_synced_at": "2026-10-14T11:48:23.606Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03315078"
    },
    {
      "nct_id": "NCT00547443",
      "title": "Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 0,
      "start_date": "2007-07",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2019-01-10",
      "last_synced_at": "2026-10-14T11:48:23.606Z",
      "location_count": 2,
      "location_summary": "Arlington, Texas • Dallas, Texas",
      "locations": [
        {
          "city": "Arlington",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00547443"
    },
    {
      "nct_id": "NCT00573443",
      "title": "Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pseudobulbar Affect (PBA)"
      ],
      "interventions": [
        {
          "name": "dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg",
          "type": "DRUG"
        },
        {
          "name": "dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Avanir Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 326,
      "start_date": "2007-12",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2017-04-12",
      "last_synced_at": "2026-10-14T11:48:23.606Z",
      "location_count": 45,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00573443"
    },
    {
      "nct_id": "NCT06576115",
      "title": "Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Nab paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "TheraBionic P1",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2025-02-28",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-10-14T11:48:23.606Z",
      "location_count": 7,
      "location_summary": "Clarkston, Michigan • Detroit, Michigan • Flint, Michigan + 4 more",
      "locations": [
        {
          "city": "Clarkston",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Flint",
          "state": "Michigan"
        },
        {
          "city": "Lansing",
          "state": "Michigan"
        },
        {
          "city": "Lapeer",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06576115"
    },
    {
      "nct_id": "NCT03388632",
      "title": "Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumors",
        "Treatment-Refractory Cancers"
      ],
      "interventions": [
        {
          "name": "rhIL-15",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Tumor biopsies",
          "type": "PROCEDURE"
        },
        {
          "name": "EKG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "ECHO",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "CT Scan",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 31,
      "start_date": "2018-02-05",
      "completion_date": "2025-05-08",
      "has_results": true,
      "last_update_posted_date": "2025-12-18",
      "last_synced_at": "2026-10-14T11:48:23.606Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03388632"
    },
    {
      "nct_id": "NCT07222163",
      "title": "Stuttering and Neuromodulation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Stuttering"
      ],
      "interventions": [
        {
          "name": "Soterix Medical 1x1 tDCS system",
          "type": "DEVICE"
        },
        {
          "name": "Speech therapy sessions",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BEHAVIORAL"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2025-09-04",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-14T11:48:23.606Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07222163"
    }
  ]
}